Charles Schwab’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-216,012
| Closed | -$22M | – | 3669 |
|
|
2023
Q2 | $22M | Buy |
216,012
+9,187
| +4% | +$869K | 0.01% | 1423 |
|
|
2023
Q1 | $18.8M | Buy |
206,825
+805
| +0.4% | +$47.2K | 0.01% | 1520 |
|
|
2022
Q4 | $7.83M | Buy |
206,020
+3,461
| +2% | +$119K | ﹤0.01% | 1987 |
|
|
2022
Q3 | $5.09M | Buy |
202,559
+7,549
| +4% | +$209K | ﹤0.01% | 2209 |
|
|
2022
Q2 | $5.93M | Sell |
195,010
-5,143
| -3% | -$153K | ﹤0.01% | 2117 |
|
|
2022
Q1 | $6.56M | Buy |
200,153
+6,526
| +3% | +$194K | ﹤0.01% | 2157 |
|
|
2021
Q4 | $5.11M | Buy |
193,627
+3,063
| +2% | +$237K | ﹤0.01% | 2342 |
|
|
2021
Q3 | $19.2M | Buy |
190,564
+4,929
| +3% | +$578K | 0.01% | 1627 |
|
|
2021
Q2 | $26.3M | Buy |
185,635
+59,185
| +47% | +$6.68M | 0.01% | 1357 |
|
|
2021
Q1 | $12.6M | Sell |
126,450
-4,308
| -3% | -$502K | ﹤0.01% | 1823 |
|
|
2020
Q4 | $16.2M | Buy |
130,758
+12,372
| +10% | +$1.63M | 0.01% | 1556 |
|
|
2020
Q3 | $11.5M | Sell |
118,386
-12,285
| -9% | -$1.53M | 0.01% | 1588 |
|
|
2020
Q2 | $20.4M | Sell |
130,671
-32,448
| -20% | -$4.93M | 0.01% | 1153 |
|
|
2020
Q1 | $23.5M | Buy |
163,119
+12,978
| +9% | +$2.51M | 0.01% | 907 |
|
|
2019
Q4 | $30.7M | Buy |
150,141
+16,913
| +13% | +$3.09M | 0.02% | 930 |
|
|
2019
Q3 | $10.7M | Buy |
133,228
+31,902
| +31% | +$2.71M | 0.01% | 1570 |
|
|
2019
Q2 | $9.56M | Buy |
101,326
+5,016
| +5% | +$433K | 0.01% | 1616 |
|
|
2019
Q1 | $8.23M | Buy |
96,310
+4,917
| +5% | +$408K | 0.01% | 1713 |
|
|
2018
Q4 | $5.13M | Sell |
91,393
-296
| -0.3% | -$18.1K | ﹤0.01% | 1892 |
|
|
2018
Q3 | $7.5M | Buy |
91,689
+20,987
| +30% | +$1.48M | 0.01% | 1818 |
|
|
2018
Q2 | $2.47M | Buy |
70,702
+21,244
| +43% | +$647K | ﹤0.01% | 2308 |
|
|
2018
Q1 | $1.01M | Buy |
49,458
+1,404
| +3% | +$36.1K | ﹤0.01% | 2509 |
|
|
2017
Q4 | $1.36M | Sell |
48,054
-1,774
| -4% | -$49.5K | ﹤0.01% | 2435 |
|
|
2017
Q3 | $1.55M | Buy |
49,828
+22,628
| +83% | +$680K | ﹤0.01% | 2369 |
|
|
2017
Q2 | $861K | Buy |
27,200
+8,400
| +45% | +$207K | ﹤0.01% | 2509 |
|
|
2017
Q1 | $426K | Hold |
18,800
| – | – | ﹤0.01% | 2702 |
|
|
2016
Q4 | $411K | Buy |
18,800
+9,700
| +107% | +$245K | ﹤0.01% | 2721 |
|
|
2016
Q3 | $240K | Buy |
+9,100
| New | +$181K | ﹤0.01% | 2866 |
|
Other funds holding RETA
Charles Schwab's RETA Position: Q3 2023 in Review
Charles Schwab sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 216,012 shares — an estimated $22M sold.
Charles Schwab first reported a position in RETA in Q3 2016 and held it in 28 quarters. The position peaked at $30.7M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Charles Schwab reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Charles Schwab sold 216,012 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $22M.
- Charles Schwab first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2016 and held it in 28 quarters.
- Charles Schwab's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $30.7M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.